Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Loic Ysebaert, Roch Houot, Olivier Casasnovas, Choquet Sylvain, Fabrice Jardin, Michael Loschi, Gabriel Brisou, Catherine Thieblemont, Jacques-Olivier Bay, Cristina Castilla-Llorente, Tom Fradon, Steven Le Gouill, Franck Morschhauser, Guillaume Cartron, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 296.

https://doi.org/10.1182/blood-2023-184653

Published: 2023

Journal Articles

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Blood (2023) 142 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2023-185632

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus or Cyclosporine a and Mycophenolate Mofetil Compared to Anti-Thymocyte Globulin tacrolimus or Cyclosporine a and Methotrexate Combinations As Graft- versus -Host Disease Prophylaxis Post Allogeneic Stem Cell Transplantation from Sibling and Unrelated Donors in Patients with Acute Myeloid Leukemia: a Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2023-174821

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gulbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Matthias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Sergeevich Moiseev, Helene Schoemans, Christian Koenecke, Zinaida Peric

Blood (2023) 142 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2023-179837

Published: 2023

Journal Articles

Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells

Blood (2023) 142 (Supplement 1): 441.

https://doi.org/10.1182/blood-2023-184788

Published: 2023

Journal Articles

Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 3498.

https://doi.org/10.1182/blood-2023-180575

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Blood (2023) 142 (Supplement 1): 1322.

https://doi.org/10.1182/blood-2023-186721

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2023-184995

Published: 2023

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2023-180686

Published: 2023

Journal Articles

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

Blood (2023) 142 (Supplement 1): 5138.

https://doi.org/10.1182/blood-2023-180241

Published: 2023

Journal Articles

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Gilles Crochet, Couturier Audrey, Emmanuel Bachy, Thomas Gastinne, Guillaume Cartron, Tom Fradon, Romain Gounot, Cristina Castilla-LLorente, Clementine Sarkozy, Vincent Camus, Stéphanie Guidez, Adrien Chauchet, Eric Deconinck, Krimo Bouabdallah, Franck Morschhauser, Roch Houot

Blood (2022) 140 (Supplement 1): 4639–4641.

https://doi.org/10.1182/blood-2022-162594

Published: 2022

Journal Articles

Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry

Federico Erbella, Emmanuel Bachy, Guillaume Cartron, Elodie Gat, Franck Morschhauser, Benoit Tessoulin, Olivier Tournilhac, Choquet Sylvain, François-Xavier Gros, Cristina Castilla-Llorente, Arnaud Campidelli, René-Olivier Casasnovas, Louise Roulin, Pierre Bories, Mohamad Mohty, Martin Carre, Steven Le Gouill, Roch Houot, Roberta Di Blasi

Blood (2022) 140 (Supplement 1): 1325–1327.

https://doi.org/10.1182/blood-2022-165352

Published: 2022

Journal Articles

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 1859–1861.

https://doi.org/10.1182/blood-2022-167840

Published: 2022

Journal Articles

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Hedi Bensaber, Emmanuel Bachy, David Beauvais, Remy Dulery, Thomas Gastinne, Bruno Villemagne, Louise Roulin, Etienne Paubelle, Cristina Castilla-Llorente, Thomas Longval, Elodie Gat, Amandine Fayard, Jacques-Olivier Bay, Steven Le Gouill, Roch Houot, Romain Guieze

Blood (2022) 140 (Supplement 1): 3803–3804.

https://doi.org/10.1182/blood-2022-158807

Published: 2022

Journal Articles

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière Wallet, Amandine Le Bourgeois, Maud D'Aveni, Anne Huynh, Ana Berceanu, Tony Marchand, Sylvain Chantepie, Carmen Botella Garcia, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Anne Thiebaut-Bertrand, Sylvie François, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen

Blood (2022) 139 (1): 134–137.

https://doi.org/10.1182/blood.2021014232

Published: 2022

Includes: Supplemental data

Journal Articles

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

Alexis Maillard, Rabah Redjoul, Marion Klemencie, Hélène Labussière, Amandine Le Bourgeois, Maud d'Aveni, Anna Berceanu, Sylvain Chantepie, Carmen Botella, Michael Loschi, Magalie Joris, Cristina Castilla-Llorente, Sylvie Francois, Mathieu Leclerc, Patrice Chevallier, Stephanie Nguyen Quoc

Blood (2021) 138 (Supplement 1): 336.

https://doi.org/10.1182/blood-2021-149495

Published: 2021

Journal Articles

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Riwa Sakr, MD, Sylvain Pilorge, MD, Stephane De Botton, Claude Chahine, MD, Tereza Coman, MD PhD, Marcel Adler, MD, Jean-Baptiste Micol, MD PhD, Florence Pasquier, MD PhD, Christophe Willekens, MD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Eric Solary, MD, Vincent Ribbag, Jean-Henri Bourhis, Cristina Castilla-LLorente, MD PhD

Blood (2017) 130 (Supplement 1): 5544.

https://doi.org/10.1182/blood.V130.Suppl_1.5544.5544

Published: 2017

NARROW

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Post-Transplant Cyclophosphamide or ATG As Gvhd Prophylaxis in Mismatched Unrelated Stem Cell Transplantation? - a Registry Analysis By the EBMT Transplant Complications Working Party

Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells

Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

1-Year Data Analysis from a Cancer Center Molecular Tumor Board Dedicated to Clonal Hematopoiesis

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients

The Impact of Risk-Adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only